Skip to content
CancerIndex

Loading the knowledge graph…

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia — knowledge graph · CancerIndex